Last reviewed · How we verify
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease. The specific aim of the proposed study is to determine whether the interaction between proton-pump inhibitors (PPIs) and clopidogrel is dependent on CYP2C19 haplotype.
Details
| Lead sponsor | Neil Kleiman, MD |
|---|---|
| Status | COMPLETED |
| Enrolment | 75 |
| Start date | 2010-01 |
| Completion | 2014-06-30 |
Conditions
- Coronary Artery Disease
Interventions
- Clopidogrel 75mg, Omeprazole 20mg
Primary outcomes
- The effect of omeprazole on platelet inhibition by clopidogrel — 3 weeks
To test whether concomitant administration of omeprazole will decrease the platelet inhibitory properties of clopidogrel in subjects with LOF mutation of CYP2C19 (known as \*2 and \*3)
Countries
United States